Jpmorgan Chase & CO Clearside Biomedical, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,364 shares of CLSD stock, worth $10,571. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,364
Previous 10,419
0.53%
Holding current value
$10,571
Previous $13,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.9 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.24 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.97 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$814,0990.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$759,7860.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $61.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...